U.S. biotech firm partners with Japanese company for cancer drug

12/16/2008 | American City Business Journals

Yakult Honsha signed a licensing pact that allows it to market Celsion's ThermoDox, an experimental cancer treatment, in Japan. Celsion, a biotech firm in Columbia, Md., will receive $2.5 million upfront and is entitled to $18 million more once the drug gets clearance from Japanese regulators. Yakult will conduct clinical studies of ThermoDox in Japan.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA